Heparin cofactor II levels are increased by the use of combined oral contraceptives. 1990

I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
Haematology Department, Middlesex Hospital, London, UK.

Heparin cofactor II (HCII) was assayed by a microtitre amidolytic substrate technique. A linear response was obtained up to 1.5 U/ml and HCII levels were not affected by freezing and thawing the plasma. The assay was validated by comparing HCII and antithrombin III (AT III) levels in AT-III-deficient plasmas and samples from critically ill patients. Higher HCII levels were found in healthy normal women than in healthy normal men (means 1.16 and 0.97 U/ml, respectively, P less than 0.01). A significant increase in HCII levels from 0.86 to 1.10 U/ml (mean values) was seen in healthy normal women starting on combined oral contraceptive (COC) preparations (P less than 0.001). Increased HCII levels were maintained over a 6-month period, but fell towards normal 14 days after stopping COC, although they were still significantly higher than before starting COCs. The discrepancy in HCII level between normal men and women may be due to COC use. In clinical studies, different reference ranges should be used for men and women, and the need for careful questioning about the use of COCs is emphasized.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003277 Contraceptives, Oral, Combined Fixed drug combinations administered orally for contraceptive purposes. Combined Oral Contraceptive,Contraceptive Agents, Female, Combined,Oral Contraceptives, Combined,Combined Oral Contraceptives,Contraceptive, Combined Oral,Contraceptives, Combined Oral,Oral Contraceptive, Combined
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I
D015844 Heparin Cofactor II A sulfated plasma protein with a MW of approximately 66kDa that resembles ANTITHROMBIN III. The protein is an inhibitor of thrombin in plasma and is activated by dermatan sulfate or heparin. It is a member of the serpin superfamily. Heparin Co-Factor II,Heparin Cofactor 2,Leuserpin 2,Protease Inhibitor Leuserpin 2,Serpin D1,Heparin Co Factor II
D020152 Antithrombin III Deficiency An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis. Antithrombin 3 Deficiency,Congenital Antithrombin III Deficiency,Deficiency, Antithrombin III,Hereditary Antithrombin Deficiency,Antithrombin 3 Deficiencies,Antithrombin III Deficiencies,Deficiencies, Antithrombin 3,Deficiencies, Antithrombin III,Deficiency, Antithrombin 3

Related Publications

I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
November 1990, Thrombosis and haemostasis,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
May 2009, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
May 1995, British journal of haematology,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
May 1988, Biochemical and biophysical research communications,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
December 1989, The Journal of laboratory and clinical medicine,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
January 1997, Advances in experimental medicine and biology,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
April 1990, La Revue du praticien,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
October 1985, Proceedings of the National Academy of Sciences of the United States of America,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
I J Mackie, and H Segal, and T Burren, and M Gallimore, and K J Walshe, and G Robinson, and S J Machin
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!